Albany, NY -- (SBWIRE) -- 12/17/2018 -- DelveInsight has announced the addition of the "Chemotherapy-induced Nausea and Vomiting (CINV) -Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of Chemotherapy-induced Nausea and Vomiting (CINV) for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and forecasted epidemiology of Chemotherapy-induced Nausea and Vomiting (CINV) from 2018 to 2027 segmented by seven major markets.
Request for sample pages
CINV (Chemotherapy Induced Nausea and Vomiting) is used to describe two of the most common and distressing side effects of cancer chemotherapy, i.e., nausea and vomiting. They cause a significant negative impact on the patients' quality of life and on their ability to comply with therapy. Nausea and vomiting can also result in anorexia, decreased performance status, metabolic imbalance, wound dehiscence, oesophagal tears, and nutritional deficiency.

Female sex and history of motion or morning sickness are clear risk factors for nausea and vomiting. About 4.4%, 7.8% and 13.8% patients who had undergone chemotherapy experienced a CINV event with their initial single-day Low Emetogenic Chemotherapy (LEC), Moderate Emetogenic Chemotherapy (MEC), or High Emeteogenic Chemotherapy (HEC) administration, respectively in the United States during the study period. Around 52.4% of patients had at least one episode of nausea or vomiting. The majority of patients received highly emetogenic chemotherapeutic regimens (69.4 %) and 77.7 % of patients received antiemetic drugs consistent with MASCC and ESMO guidelines. In the United States, despite the use of standardized anti-emetic guidelines, up to 20% of cancer patients suffer from moderate-to-severe chemotherapy-induced nausea and vomiting (CINV). It has also been observed that despite the extensive use of antiemetics, chemotherapy-induced nausea continues to be reported by up to 70% of adult patients receiving moderately and highly emetogenic chemotherapy agents and 58% of school age and adolescent age children receiving highly emetogenic chemotherapy.

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027
Drug Companies
1. Novartis
2. Eisai
3. Merck Sharp and Dohme Ltd
4. Tesaro
And many others
Drugs covered

1. Zofran
2. Aloxi
3. Emend
4. Varubi
And many others

Report Scope
The report covers a descriptive overview of Chemotherapy-induced Nausea and Vomiting (CINV) explaining its pathophysiology, disease classification, diagnostic approaches and treatment algorithm. The report provides insight into the epidemiology of the disease and its treatment in the 7 MM covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan. The report is a comprehensive account of both the current and emerging therapies covering the impact of the new therapies on the current treatment landscape. The report also reviews the detailed historical and forecasted Chemotherapy-induced Nausea and Vomiting (CINV) market size covering the drug outreach in 7MM. The report provides an understanding of the future competition in Chemotherapy-induced Nausea and Vomiting (CINV) by reviewing the market drivers and barriers.